Nasdaq

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
Nasdaq

Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
Business Wire

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...
Business Wire

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...
MD&M East

Axonics F15 Recharge-Free SNM Nabs Australian TGA Approval

Axonics recently announced it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) to market the Axonics F15 recharge-free sacral neuromodulation (SNM) system for ...